U.S. Markets closed

Anika Therapeutics, Inc. (ANIK)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.91-1.04 (-2.12%)
At close: 4:00PM EDT

47.90 -0.01 (-0.02%)
After hours: 4:33PM EDT

People also watch
AMRICBMHSKAALNYARQL
Full screen
Previous Close48.95
Open49.32
Bid45.94 x 100
Ask49.00 x 100
Day's Range47.61 - 49.32
52 Week Range41.38 - 53.50
Volume63,867
Avg. Volume108,185
Market Cap701.88M
Beta1.11
PE Ratio (TTM)23.12
EPS (TTM)2.07
Earnings DateJul 26, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.50
Trade prices are not sourced from all markets
  • Zacks3 days ago

    The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics

    The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics

  • Business Wire4 days ago

    Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC

    Anika Therapeutics, Inc. , a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will receive a $5 million milestone payment under the terms of the Company’s license agreement with its U.S.

  • American City Business Journals4 days ago

    Anika pays former medical chief $350K to thwart possible lawsuit

    Back in January, Bedford-based Anika Therapeutics disclosed in a one-sentence federal filing that one of its top executives, chief medical officer Stephen Mascioli, had left the company after less than a year on the job. Anika (ANIK) said Friday that it had agreed to pay Mascioli $350,000 for “alleged damages and attorneys’ fees,” including $250,000 for alleged lost wages. While the filing did not disclose the nature of Mascioli’s allegations, it said that he had agreed not to pursue any legal action against Anika, including potential claims for age discrimination and retaliation.